CDK9 and neoplasm: Combination treatment with the CDK9 inhibitor LDC000067 and the BET inhibitor BI 894999 led to a strong reduction in global RNA pol II Ser2 phosphorylation levels and a marked induction of apoptosis in vitro and in vivo, and synergistically induced tumour regression compared to single agents [215].